1054-P: Characterizing Clinical and Economic Outcomes among Patients with MASH and Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 (GLP1)—A Cohort Study

Introduction & Objective: Metabolic-dysfunction associated steatohepatitis (MASH; or NASH) affects 3-6% of adults in the US; many also receive GLP1 for type II diabetes mellitus (T2DM) and/or obesity. This study aimed to characterize clinical and economic outcomes among patients with MASH and T2...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1
Hauptverfasser:	KIM, YESTLE, QIAN, CHRISTINA, FISHMAN, JESSE, SZABO, SHELAGH M., ROCHON, HANNAH, SUN, ROSIE, MEDICIS, JOE, CHARLTON, MICHAEL
Format:	Artikel
Sprache:	eng
Schlagworte:	Body weight Cirrhosis Diabetes Diabetes mellitus (non-insulin dependent) Glucagon Glucagon-like peptide 1 Liver cirrhosis Liver diseases Liver transplantation Obesity Overweight Patients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!